NDAINTRAVENOUSSOLUTION
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
BIORPHEN (phenylephrine hydrochloride) by Dr. Reddy's Laboratories is α-1 adrenergic receptor agonist. Approved for nasal congestion, seasonal allergic rhinitis, vasomotor rhinitis. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIORPHEN is an intravenous solution of phenylephrine hydrochloride, an α-1 adrenergic receptor agonist approved in October 2019. It is indicated for nasal congestion, seasonal allergic rhinitis, and vasomotor rhinitis through selective activation of alpha-1 adrenergic receptors. This small-molecule sympathomimetic agent works by constricting blood vessels in nasal tissues to reduce congestion.
Peak
Product is in peak commercial phase with stable reimbursement but faces moderate competitive pressure (30% intensity); brand team focus likely on market maintenance and niche positioning within institutional/acute care channels.
Mechanism of Action
α-1 adrenergic receptor agonist.
Indications (3)
Worked on BIORPHEN at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.